Floatz logo

Brigatinib

Other Solid Tumor

Princess Maxima Center for Pediatric OncologySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Other Solid Tumor cohort.

Asset / SponsorPhaseRating
Rucaparib
pharmaand GmbH
Phase 3B
Autologous, Engineered T Cells Targeting Tp53 R248Q
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1C

Same molecule, other indications

Brigatinib is also rated in:

cancerDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →